Leuprorelin is a gonadotropin-releasing hormone (GnRH) agonist and a synthetic nonapeptide analogue of a naturally occurring. When administered continuously, Leuprorelin inhibits pituitary gonadotropin secretion and suppresses testicular and ovarian steroidogenesis.

The company's leuprorelin injectable emulsion is developed based on Taiwan Foresee Pharmaceuticals's new generation of in situ gel technology platform SIF long-acting in situ gel platform, with technical advantages such as low production cost, stable drug properties, convenient use, and longer sustained release period. The product includes two specifications of 3 months and 6 months, and has currently carried out relevant clinical work such as advanced prostate cancer, central precocious puberty in children, and premenopausal breast cancer. In terms of advanced prostate cancer, the last case of Phase III clinical trial has been enrolled, and the latest clinical data show that the main efficacy indicators of the clinical trials of related products have met the standards; in terms of central precocious puberty in children, this product is currently the first 6-month long-acting in situ gel preparation approved for clinical trial in China for the treatment of central precocious puberty in children. During the reporting period, the Phase III clinical trial has completed the first patient enrollment.